The Arizona Clinical Oncology Society | Association Partnerships

home / partners / the-arizona-clinical-oncology-society

Founded in 1991, The Arizona Clinical Oncology Society (TACOS) is the largest oncology professional organization in the state. TACOS comprises a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers involved in the treatment of patients with cancer.

TACOS is one of 22 State Chapter Members managed by the Association of Community Cancer Centers (ACCC) and is a State Affiliate of the American Society of Clinical Oncology. Members receive valuable educational content and innovative resources designed to keep them ahead of the local and national challenges and trends directly impacting the high-quality care their patients deserve.

For more information, resources, and upcoming events visit tacos-oncology.com.

Connect with us:

Latest from The Arizona Clinical Oncology Society

Zakharia Evaluates Available Combination Options for Non–Clear Cell RCC

Zakharia Evaluates Available Combination Options for Non–Clear Cell RCC

Targeted Oncology Staff
October 19th 2024

Yousef Zakharia, MD, discussed some of the available combination therapies for non–clear cell renal cell carcinoma treatment.

Read More

Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC

Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC

Targeted Oncology Staff
April 22nd 2024

During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.

Read More

The Growing Role of Immunotherapy in Targeting NSCLC

The Growing Role of Immunotherapy in Targeting NSCLC

Targeted Oncology Staff
August 30th 2023

During a Targeted Oncology™ Community Case Forum™ event in partnership with The Arizona Clinical Oncology Society, Sujith R. Kalmadi, MD, reviewed data from the most important recent phase 3 trials of chemoimmunotherapy in advanced non–small cell lung cancer.

Read More

20 Years of Trials, Hope and Progress for Patients with Pancreatic Adenocarcinoma

20 Years of Trials, Hope and Progress for Patients with Pancreatic Adenocarcinoma

Tomislav Dragovich, MD, PhD
December 21st 2022

In a comprehensive review of the last 20 years of advancements and challenges in the pancreatic adenocarcinoma landscape, Dr. Tomsilav Dragovich highlights how treatment has evolved for this patient population.

Read More

Pancreatic Cancer Awareness Month: Novel Targeted Therapy in PDAC

Pancreatic Cancer Awareness Month: Novel Targeted Therapy in PDAC

Binbin Zheng-Lin, MD, MSc;Tanios Bekaii -Saab, MD
November 30th 2022

The landscape for patients with pancreatic ductal adenocarcinoma has shifted due to novel targeted therapies that are opening new options for patients.

Read More

World Pancreatic Cancer Awareness Day: Advances in Pancreatic Cancer Detection and Treatment

World Pancreatic Cancer Awareness Day: Advances in Pancreatic Cancer Detection and Treatment

Lynn M. Matrisian, PhD, MBA;Allison Rosenzweig, PhD
November 18th 2021

Lynn M. Matrisian, PhD, MBA, and Allison Rosenzweig, PhD, from Pancreatic Cancer Action Network, review advances in the pancreatic cancer setting for World Pancreatic Cancer Awareness Day.

Read More